Turner Liam Daniel, Conrad Diana
Ophthalmology Department, The Royal Brisbane and Women's Hospital, 10/87 Hampstead Road, Highgate Hill, Brisbane, QLD, 4101, Australia.
BMC Res Notes. 2015 Oct 31;8:627. doi: 10.1186/s13104-015-1591-0.
The purpose of this study was to report: (1) the varying presentation of Paecilomyces ocular infections arising in Queensland; (2) the significance of immunosuppression as a primary determinant of disease; (3) the outcomes of voriconazole use; and (4) the ongoing need for both surgical and medical management of this devastating fungal infection.
A retrospective case series of 21 culture proven individuals participated in this series and were identified via a review of the pathology reporting system utilized in the Queensland public health system. All culture proven individuals were subjected to a systematic chart review.
The primary risk factor for Paecilomyces lilacinus infection is immunosuppression with 81.25 % of individuals being on some form of immunosuppression (i.e. systemic or topical). Of the cases 71.43 % had an intact epithelial surface at the time of diagnosis, and 76 % had no previous ocular history. The final visual outcomes were nine cases with HM vision or worse, three cases with 6/48-6/60 vision, three cases 6/12-6/24, and six cases with 6/12 vision or better. Despite voriconazole use rates of greater than 80 %, protracted and poor treatment outcomes continue to be commonplace.
Paecilomyces lilacinus is a filamentous fungus that has a predilection for immunosuppressed individuals. Despite in vitro and case reports demonstrating the effectiveness of voriconazole poor outcomes continue to be seen.
本研究的目的是报告:(1)昆士兰州出现的淡紫拟青霉眼部感染的不同表现;(2)免疫抑制作为疾病主要决定因素的重要性;(3)伏立康唑的使用结果;以及(4)对这种毁灭性真菌感染进行手术和药物治疗的持续需求。
对21例经培养证实的病例进行回顾性病例系列研究,通过回顾昆士兰公共卫生系统使用的病理报告系统来确定这些病例。所有经培养证实的病例均进行了系统的病历审查。
淡紫拟青霉感染的主要危险因素是免疫抑制,81.25%的患者接受某种形式的免疫抑制(即全身或局部)。在这些病例中,71.43%在诊断时上皮表面完整,76%既往无眼部病史。最终视力结果为9例视力为眼前手动或更差,3例视力为6/48 - 6/60,3例视力为6/12 - 6/24,6例视力为6/12或更好。尽管伏立康唑使用率超过80%,但长期和不良的治疗结果仍然很常见。
淡紫拟青霉是一种丝状真菌,易感染免疫抑制个体。尽管体外研究和病例报告显示伏立康唑有效,但仍可见到不良结果。